Beta-blockers in cirrhosis: Friend and foe?

Hepatology

Volumn 52, Issue 3, 2010, Pages 811-813

  Wong, Florence ^a   Salerno, Francesco ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ISOSORBIDE MONONITRATE; NADOLOL; NITRIC ACID DERIVATIVE; PROPRANOLOL;

ASCITES; ASTHMA; ATRIOVENTRICULAR BLOCK; CARDIOMYOPATHY; CHRONIC DRUG ADMINISTRATION; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EDITORIAL; ESOPHAGUS VARICES BLEEDING; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPOTENSION; KIDNEY FAILURE; KIDNEY PERFUSION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORTALITY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RESPIRATORY FAILURE; RISK BENEFIT ANALYSIS; SEPSIS; SPLANCHNIC BLOOD FLOW; COMPLICATION; ESOPHAGEAL AND GASTRIC VARICES; PERITONITIS; RENAL INSUFFICIENCY; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; ESOPHAGEAL AND GASTRIC VARICES; HUMANS; KIDNEY FAILURE; LIVER CIRRHOSIS; PERITONITIS; PROPRANOLOL; RISK FACTORS; RENAL INSUFFICIENCY;

EID: 77956645446     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23852     Document Type: Editorial

References (20)

1. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231.
2. Stokkeland K, Brandt L, Ekbom A, Hultcrantz R. Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969-2002. HEPATOLOGY 2006;43:500-505.
3. Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med 1981;305:1371-1374. (Pubitemid 12236180)
4. Mehta G, Abraldes G, Bosch J. Developments and controversies in the managements of esophageal and gastric varices. Gut 2010;59:701-705.
5. North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988;319:983-989.
6. Garcia- Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010;362:823-832.
7. D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006;131:1611-1624.
8. Borroni G, Salerno F, Cazzaniga M, Bissoli F, Lorenzano E, Maggi A, et al. Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. J Hepatol 2002;37:315-321.
9. Sersté TS, Melot C, Francoz C, Durand F, Rautou PE, Vella DC, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. HEPATOLOGY 2010;52:1017-1022.
10. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. HEPATOLOGY 2003;38:258-266.
11. Ruiz del Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, Albillos A, et al. Cardiovascular, renal and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. HEPATOLOGY 2003;38:1210-1218.
12. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Ginès P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. HEPATOLOGY 2005;42:439-447.
13. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. HEPATOLOGY 1988;8:1151-1157.
14. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The effect of cirrhotic cardiomyopathy on the cardiac response to exercise in cirrhosis. Gut 2001;49:268-275.
15. Wong F. Cirrhotic cardiomyopathy. Hepatol Int 2009;3:294-304.
16. Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular portosystemic shunt. Am J Gastroenterol 2009;104:2458-2466.
17. Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010;59:105-110.
18. Senzolo M, Cholongitas E, Burra P, Leandro G, Thalheimer U, Patch D, Burroughs AK. Beta-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009;29:1189-1193.
19. Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell'Era A, Bosch J. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol 2006;101:506-512. (Pubitemid 43340926)
20. Thalheimer U, Bosch J, Burroughs AK. How to prevent varices from bleeding: shades of grey: the case for nonselective beta-blockers. Gastroenterology 2007;133:2029-2036.